This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV1501 (ABL001).
Epistemonikos ID: bb3cd8ab575d249dbdb729d8162024152e801caa
First added on: May 21, 2024